Taysha Gene Therapies, Inc. (TSHA)
NASDAQ · Manufacturing · Biological products, (no diagnostic substances)
$4.67−$0.1200 (−2.51%) on the dayAs of the close; data may be delayed.
TSHA price, last 12 months
Key stats
- Previous close
- $4.79
- Open
- $4.85
- Day range
- $4.67 – $4.88
- 52-week range
- $3.04 – $7.30
- Volume
- 2.6M
- Avg volume (20 days)
- 3.4M
- Market cap
- $1.5B
Performance
1W−7.0%
1M−22.4%
3M−26.3%
6M+8.1%
YTD−15.1%
1Y+48.3%
vs S&P 500, 1Y+31.5 pts
Technicals and fundamentals
About Taysha Gene Therapies, Inc.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.
- Sector
- Manufacturing
- Industry
- Biological products, (no diagnostic substances)
- Listed on
- NASDAQ
- Market cap
- $1.5B